Intrexon (XON) Misses Q3 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- Wall St futures rise as Treasury yields cool, oil slips
- Oil slips as Mideast exports, G7 stockpile ease supply concerns
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Citi cuts investment banking analyst program to two years - Bloomberg
- Paramount Skydance to close WBD deal, change ticker to SKYD
- HubSpot to cut 7% of workforce in restructuring plan
- Nasdaq notches record high close as investors focus on earnings
- Francis Halzen wins Nobel Physics Prize for Antarctic 'ghost particle' hunt
Intrexon Announces Third Quarter 2015 Financial Results
November 9, 2015 4:05 PM ESTGERMANTOWN, Md., Nov. 9, 2015 /PRNewswire/ --Â Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its third quarter results for 2015.Â
Business Highlights and Recent Developments:
During the third quarter, Intrexon and the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, furthered research and development efforts with the collaboration's first two chimeric antigen receptor (CAR) T-cell targets of interest and are advancing these targets to... More


